Late-life depression symptom profiles are differentially associated with immunometabolic functioning

Brain, Behavior, and Immunity

Volumn 41, Issue 1, 2014, Pages 109-115

  Vogelzangs, Nicole ^a   Comijs, Hannie C ^a   Oude Voshaar, Richard C ^b   Stek, Max L ^a   Penninx, Brenda W J H ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Cohort study; Depression; Elderly; Inflammation; Metabolic syndrome

Indexed keywords

ANTIDEPRESSANT AGENT; C REACTIVE PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; TRIACYLGLYCEROL; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; IL6 PROTEIN, HUMAN; LIPID;

AGED; ARTICLE; BLOOD PRESSURE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DIET RESTRICTION; DISEASE SEVERITY; DOWN REGULATION; DSM-IV; FEMALE; GERIATRIC DEPRESSION SCALE; GLUCOSE BLOOD LEVEL; HUMAN; IMMUNOLOGICAL PARAMETERS; LATE LIFE DEPRESSION; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; METABOLIC SYNDROME X; MINI MENTAL STATE EXAMINATION; ONSET AGE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; UPREGULATION; WAIST CIRCUMFERENCE; ANALYSIS; BLOOD; CHRONIC DISEASE; CLASSIFICATION; CLINICAL TRIAL; COMORBIDITY; DEPRESSIVE DISORDER; DRINKING BEHAVIOR; FOLLOW UP; IMMUNOLOGY; LIFESTYLE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; NETHERLANDS; PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; SMOKING; VERY ELDERLY;

AGE OF ONSET; AGED; AGED, 80 AND OVER; ALCOHOL DRINKING; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; C-REACTIVE PROTEIN; CHRONIC DISEASE; COMORBIDITY; DEPRESSIVE DISORDER; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERLEUKIN-6; LIFE STYLE; LIPIDS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NETHERLANDS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SMOKING;

EID: 84924080614     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2014.05.004     Document Type: Article

References (49)

1. Akbaraly T.N., Ancelin M.L., Jaussent I., Ritchie C., Barberger-Gateau P., Dufouil C., Kivimaki M., Berr C., Ritchie K. Metabolic syndrome and onset of depressive symptoms in the elderly: findings from the three-city study. Diab. Care 2011, 34:904-909.
2. Allison D.B., Gallagher D., Heo M., Pi-Sunyer F.X., Heymsfield S.B. Body mass index and all-cause mortality among people age 70 and over: the longitudinal study of aging. Int. J. Obes. Relat. Metab. Disord. 1997, 21:424-431.
3. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 2001, American Psychiatric Association, Washington, DC. fourth ed.
4. Bremmer M.A., Deeg D.J., Beekman A.T., Penninx B.W., Lips P., Hoogendijk W.J. Major depression in late life is associated with both hypo- and hypercortisolemia. Biol. Psychiatry 2007, 62:479-486.
5. Buchman A.S., Wilson R.S., Bienias J.L., Shah R.C., Evans D.A., Bennett D.A. Change in body mass index and risk of incident Alzheimer disease. Neurology 2005, 65:892-897.
6. Comijs H.C., van Marwijk H.W., van der Mast R.C., Naarding P., Oude Voshaar R.C., Beekman A.T., Boshuisen M., Dekker J., Kok R., de Waal M.W., Penninx B.W., Stek M.L., Smit J.H. The Netherlands study of depression in older persons (NESDO); a prospective cohort study. BMC Res. Notes 2011, 4:524.
7. Craig C.L., Marshall A.L., Sjostrom M., Bauman A.E., Booth M.L., Ainsworth B.E., Pratt M., Ekelund U., Yngve A., Sallis J.F., Oja P. International physical activity questionnaire: 12-country reliability and validity. Med. Sci. Sports Exerc. 2003, 35:1381-1395.
8. Dowlati Y., Herrmann N., Swardfager W., Liu H., Sham L., Reim E.K., Lanctot K.L. A meta-analysis of cytokines in major depression. Biol. Psychiatry 2010, 67:446-457.
9. Duivis H.E., de J.P., Penninx B.W., Na B.Y., Cohen B.E., Whooley M.A. Depressive symptoms, health behaviors, and subsequent inflammation in patients with coronary heart disease: prospective findings from the heart and soul study. Am. J. Psychiatry 2011, 168:913-920.
10. Eller T., Vasar V., Shlik J., Maron E. Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:445-450.
11. Fries E., Hesse J., Hellhammer J., Hellhammer D.H. A new view on hypocortisolism. Psychoneuroendocrinology 2005, 30:1010-1016.
12. Giltay E.J., van Reedt Dortland A.K., Nissinen A., Giampaoli S., van V.T., Zitman F.G., Bots S., Kromhout D. Serum cholesterol, apolipoprotein E genotype and depressive symptoms in elderly European men: the FINE study. J. Affect. Disord. 2009, 115:471-477.
13. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., Gordon D.J., Krauss R.M., Savage P.J., Smith S.C., Spertus J.A., Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752.
14. Haffner S.M. The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am. J. Cardiol. 2006, 97:3A-11A.
15. Hamer M., Batty G.D., Marmot M.G., Singh-Manoux A., Kivimaki M. Anti-depressant medication use and C-reactive protein: results from two population-based studies. Brain Behav. Immun. 2011, 25:168-173.
16. Hannestad J., DellaGioia N., Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 2011, 36:2452-2459.
17. Hiles S.A., Baker A.L., de M.T., Attia J. Interleukin-6, C-reactive protein and interleukin-10 after antidepressant treatment in people with depression: a meta-analysis. Psychol. Med. 2012, 1-12.
18. Howren M.B., Lamkin D.M., Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom. Med. 2009, 71:171-186.
19. Inventory of Depressive Symptomatology (IDS) and Quick Inventory of Depressive Symptomatology (QIDS). (accessed 2013). http://www.ids-qids.org.
20. Kahl K.G., Greggersen W., Schweiger U., Cordes J., Balijepalli C., Losch C., Moebus S. Prevalence of the metabolic syndrome in unipolar major depression. Eur. Arch. Psychiatry Clin. Neurosci. 2012, 262:313-320.
21. Kaplan R.C., Tirschwell D.L., Longstreth W.T., Manolio T.A., Heckbert S.R., LeValley A.J., Lefkowitz D., El-Saed A., Psaty B.M. Blood pressure level and outcomes in adults aged 65 and older with prior ischemic stroke. J. Am. Geriatr. Soc. 2006, 54:1309-1316.
22. Khan A.Y., Carrithers J., Preskorn S.H., Lear R., Wisniewski S.R., John R.A., Stegman D., Kelley C., Kreiner K., Nierenberg A.A., Fava M. Clinical and demographic factors associated with DSM-IV melancholic depression. Ann. Clin. Psychiatry 2006, 18:91-98.
23. Kinder L.S., Carnethon M.R., Palaniappan L.P., King A.C., Fortmann S.P. Depression and the metabolic syndrome in young adults: findings from the Third National Health and Nutrition Examination Survey. Psychosom. Med. 2004, 66:316-322.
24. Kinser P.A., Lyon D.E. Major depressive disorder and measures of cellular aging: an integrative review. Nurs. Res. Pract. 2013, 2013:469070.
25. Kloiber S., Ising M., Reppermund S., Horstmann S., Dose T., Majer M., Zihl J., Pfister H., Unschuld P.G., Holsboer F., Lucae S. Overweight and obesity affect treatment response in major depression. Biol. Psychiatry 2007, 62:321-326.
26. Kuo S.Y., Lin K.M., Chen C.Y., Chuang Y.L., Chen W.J. Depression trajectories and obesity among the elderly in Taiwan. Psychol. Med. 2011, 41:1665-1676.
27. Lamers F., Vogelzangs N., Merikangas K.R., de J.P., Beekman A.T., Penninx B.W. Evidence for a differential role of HPA-axis function, inflammation and metabolic syndrome in melancholic versus atypical depression. Mol. Psychiatry 2013, 18:692-699.
28. Lanquillon S., Krieg J.C., ing-Abu-Shach U., Vedder H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 2000, 22:370-379.
29. Licht C.M., Vreeburg S.A., van Reedt Dortland A.K., Giltay E.J., Hoogendijk W.J., Derijk R.H., Vogelzangs N., Zitman F.G., Degeus E.J., Penninx B.W. Increased sympathetic and decreased parasympathetic activity rather than changes in hypothalamic-pituitary-adrenal axis activity is associated with metabolic abnormalities. J. Clin. Endocrinol. Metab. 2010, 95:2458-2466.
30. Lyness J.M. Depression and comorbidity: objects in the mirror are more complex than they appear. Am. J. Geriatr. Psychiatry 2008, 16:181-185.
31. Marijnissen R.M., Naude P.J., Comijs H.C., Schoevers R.A., Oude Voshaar R.C. Waist circumference and neutrophil gelatinase-associated lipocalin in late-life depression. Brain Behav. Immun. 2014, 37:231-239.
32. Miller A.H., Maletic V., Raison C.L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry 2009, 65:732-741.
33. *D. J. Clin. Psychiatry 2005, 66:1002-1011.
34. Pan A., Keum N., Okereke O.I., Sun Q., Kivimaki M., Rubin R.R., Hu F.B. Bidirectional association between depression and metabolic syndrome: a systematic review and meta-analysis of epidemiological studies. Diab. Care 2012, 35:1171-1180.
35. Penninx B.W., Beekman A.T., Bandinelli S., Corsi A.M., Bremmer M., Hoogendijk W.J., Guralnik J.M., Ferrucci L. Late-life depressive symptoms are associated with both hyperactivity and hypoactivity of the hypothalamo-pituitary-adrenal axis. Am. J. Geriatr. Psychiatry 2007, 15:522-529.
36. Penninx B.W., Milaneschi Y., Lamers F., Vogelzangs N. Understanding the somatic consequences of depression: biological mechanisms and the role of depression symptom profile. BMC Med. 2013, 11:129.
37. Pyykkonen A.J., Raikkonen K., Tuomi T., Eriksson J.G., Groop L., Isomaa B. Association between depressive symptoms and metabolic syndrome is not explained by antidepressant medication: results from the PPP-Botnia Study. Ann. Med. 2012, 44:279-288.
38. Rush A.J., Gullion C.M., Basco M.R., Jarrett R.B., Trivedi M.H. The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol. Med. 1996, 26:477-486.
39. Siennicki-Lantz A., Andre-Petersson L., Elmstahl S. Decreasing blood pressure over time is the strongest predictor of depressive symptoms in octogenarian men. Am. J. Geriatr. Psychiatry 2013, 21:863-871.
40. Sutherland J.P., McKinley B., Eckel R.H. The metabolic syndrome and inflammation. Metab. Syndr. Relat. Disord. 2004, 2:82-104.
41. Van Cauter E., Leproult R., Kupfer D.J. Effects of gender and age on the levels and circadian rhythmicity of plasma cortisol. J. Clin. Endocrinol. Metab. 1996, 81:2468-2473.
42. van Reedt Dortland A.K., Giltay E.J., van V.T., Zitman F.G., Penninx B.W. Metabolic syndrome abnormalities are associated with severity of anxiety and depression and with tricyclic antidepressant use. Acta Psychiatr. Scand. 2010, 122:30-39.
43. Viinamaki H., Heiskanen T., Lehto S.M., Niskanen L., Koivumaa-Honkanen H., Tolmunen T., Honkalampi K., Saharinen T., Haatainen K., Hintikka J. Association of depressive symptoms and metabolic syndrome in men. Acta Psychiatr. Scand. 2009, 120:23-29.
44. Vogelzangs N., Beekman A.T., Dik M.G., Bremmer M.A., Comijs H.C., Hoogendijk W.J., Deeg D.J., Penninx B.W. Late-life depression, cortisol, and the metabolic syndrome. Am. J. Geriatr. Psychiatry 2009, 17:716-721.
45. Vogelzangs N., Duivis H.E., Beekman A.T., Kluft C., Neuteboom J., Hoogendijk W., Smit J.H., de J.P., Penninx B.W. Association of depressive disorders, depression characteristics and antidepressant medication with inflammation. Transl. Psychiatry 2012, 2:e79.
46. Whitmer R.A., Gunderson E.P., Quesenberry C.P., Zhou J., Yaffe K. Body mass index in midlife and risk of Alzheimer disease and vascular dementia. Curr. Alzheimer Res. 2007, 4:103-109.
47. WHO Collaborating Centre for Drug Statistics Methodology Anatomical Therapeutic Chemical Classification 2007, World Health Organization, Geneva.
48. Wittchen H.U. Reliability and validity studies of the WHO-Composite International Diagnostic Interview (CIDI): a critical review. J. Psychiatr. Res. 1994, 28:57-84.
49. Yesavage J.A. Geriatric depression scale. Psychopharmacol. Bull. 1988, 24:709-711.